Talazoparib

Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer

Retrieved on: 
Tuesday, September 13, 2022
Safety, NYSE, FDA, Disease, ANN, Talazoparib, Melanoma, Patient, Stata, Cancer, Axitinib, PFE, RNA, MRD, DNA, Neoplasm, Angiogenesis, Pharmaceutical industry, Medical imaging, Stratum, Pfizer

ANN ARBOR, Mich., Sept. 13, 2022 /PRNewswire/ -- Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced expansion of its clinical collaboration with Pfizer (NYSE: PFE) in the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial. Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations. Pfizer will provide Braftovi® (encorafenib), Mektovi® (binimetinib), and Lorbrena® (lorlatinib) for up to six new cohorts of patients with early-stage lung, melanoma, colorectal, and other cancers who have evidence of micrometastatic disease after initial treatment. Pfizer is already providing Strata with Braftovi® (encorafenib), Mektovi® (binimetinib), Lorbrena® (lorlatinib), Talzenna® (talazoparib), and Inlyta (axitinib) for evaluation in four late-stage cohorts of the Strata PATH trial.

Key Points: 
  • a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced expansion of its clinical collaboration with Pfizer (NYSE: PFE) in the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial.
  • Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations.
  • Pfizer is already providing Strata with Braftovi (encorafenib), Mektovi(binimetinib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Inlyta (axitinib) for evaluation in four late-stage cohorts of the Strata PATH trial.
  • Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer.

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Retrieved on: 
Wednesday, August 10, 2022
Merck Group, Institute of Cancer Research, HIV disease progression rates, ATR, PARP, Drug discovery, Breast cancer, Industry, DNA repair, MD Anderson Cancer Center, NEW, The Institute, Toxicity, De novo, Research, Cancer, Neoplasm, Patient, DNA, Therapy, Institute, DDR, Associate, Netherlands Cancer Institute, Biotechnology, Olaparib, Sarah Cannon Research Institute, Safety, Francis Crick Institute, Talazoparib, List of life sciences, Novartis, Partnership, MMEJ, University, ADP, Nature Communications, Cancer Research UK, Medical director, Oncology nursing, Pharmacokinetics, Pharmaceutical industry, Medical imaging, Casting Society of America

ART4215 is the first selective, oral, small molecule inhibitor of the Pol polymerase domain to enter the clinic.

Key Points: 
  • ART4215 is the first selective, oral, small molecule inhibitor of the Pol polymerase domain to enter the clinic.
  • Extensive preclinical studies have demonstrated that ART4215 has broad potential clinical utility, as described in Artios recent Nature Communications publication, Zatreanu et al., 2021.
  • The Pol project was originally in-licensed from Cancer Research Technology (now Cancer Research Horizons) in 2016 as part of the initial formation of Artios.
  • A recommended Phase 2 dose has been established for ART4215 in combination with talazoparib, and a randomized expansion cohort has been initiated to evaluate the combination in patients with BRCA deficient breast cancer.

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Retrieved on: 
Wednesday, August 10, 2022
HIV disease progression rates, PARP, Breast cancer, GLOBE, NEW, MD Anderson Cancer Center, Toxicity, De novo, Cancer, Neoplasm, Patient, Institute, DNA, Therapy, DDR, Associate, Sarah Cannon Research Institute, Safety, Talazoparib, MMEJ, University, ADP, Nature Communications, Medical director, Oncology nursing, Pharmacokinetics, Pharmaceutical industry, Medical imaging, Casting Society of America

ART4215 is the first selective, oral, small molecule inhibitor of the Pol polymerase domain to enter the clinic.

Key Points: 
  • ART4215 is the first selective, oral, small molecule inhibitor of the Pol polymerase domain to enter the clinic.
  • Extensive preclinical studies have demonstrated that ART4215 has broad potential clinical utility, as described in Artios recent Nature Communications publication, Zatreanu et al., 2021.
  • We are highly encouraged that ART4215 may offer a new treatment option that can synergize to overcome both de novo and acquired PARP resistance.
  • A recommended Phase 2 dose has been established for ART4215 in combination with talazoparib, and a randomized expansion cohort has been initiated to evaluate the combination in patients with BRCA deficient breast cancer.

Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)

Retrieved on: 
Tuesday, June 21, 2022
Population, Beti, Ipilimumab, ADP, Merck, BRCA, Clinical trial, Talazoparib, BET, University, Targeted therapy, ASCO, RAD51, Disorder, GLOBE, Neoplasm, Pembrolizumab, Therapy, Poster, Institute, CEO, Breast, National, DNA, Mutation, 2021 Essex County Council election, National Cancer Institute, MCRPC, Astellas Pharma, University of California, San Francisco, HER2, PR, Nivolumab, TNBC, Ovarian cancer, Parpi, Adult, Patient, Woman, BMS, Breast cancer, Zenith, PARP, Institut Jules Bordet, Cancer, Trial of the century, Conversation, Program, Pfizer, Prognosis, GRASP, Pharmaceutical industry, EU

The poster can be viewed on Zenith Epigenetics website ( Poster ) and the discussion can be viewed on the ASCO website ( Discussion ).

Key Points: 
  • The poster can be viewed on Zenith Epigenetics website ( Poster ) and the discussion can be viewed on the ASCO website ( Discussion ).
  • Zenith has expanded the Phase 2 trial to continue to evaluate the combination in an additional 120 mTNBC patients ( NCT03901469 ).
  • The combination regimen of ZEN-3694 + talazoparib has shown promising clinical activity in a mTNBC patient population with significant unmet need.
  • Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib), conducted in collaboration with Pfizer and Newsoara Biopharma.

Global PARP Inhibitors Cancer Therapy Market Report 2022-2028: Patent Expiration, Pricing, Dosage, Sales Analysis, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 8, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Olaparib, Fallopian tube cancer, Immunotherapy, Radiation, PARP, Company, Protein, Research, DNA repair, EMA, Lists of World Heritage Sites, Survival, PI3K, Patent, Niraparib, C1-inhibitor, Breast cancer, Peritonitis, Cancer, Indication, Rucaparib, Pancreatic cancer, Therapy, Global, Ovarian cancer, US FDA, DDR, Growth, Patient, Risk, DNA, MEK, CDK, Enzyme, Strategic planning, ADP, Pharmaceutical industry, Vaccine, Talazoparib, Carcinogenesis

The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 report is a comprehensive analysis of a variety of factors that are prevalent in the PARP Inhibitors.
  • Currently marketed PARP Inhibitors are approved for treating breast cancer, ovarian cancer, fallopian tube cancer; primary peritoneal cancer, and pancreatic cancer.
  • "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report highlights:
    Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion
    Global PARP Clinical Trials Insight by Company, Country, Indication & Phase
    Regional Analysis Based On Drug Approvals: US, Europe, China & Japan
    3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair

Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

Retrieved on: 
Tuesday, May 10, 2022
Disorder, ASCO, MCRPC, Pfizer, Parpi, University, Memorial Sloan Kettering Cancer Center, Woman, GLOBE, Pembrolizumab, Neoplasm, BRCA, RAD51, Merck, University of California, San Francisco Fetal Treatment Center, Safety, Breast cancer, Nivolumab, Patient, PR, National Cancer Institute, BET, Clinical trial, National, Cancer, Therapy, DNA, Talazoparib, Ovarian cancer, Breast, ADP, Adult, Prognosis, Ipilimumab, Astellas Pharma, BMS, CEO, PARP, TNBC, HER2, Pharmaceutical industry, Medical imaging, EU, Zenith

CALGARY, Alberta, May 10, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (Zenith or the Company) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical trial combining ZEN-3694 + Pfizer Inc.s Talzenna (talazoparib).

Key Points: 
  • CALGARY, Alberta, May 10, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (Zenith or the Company) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical trial combining ZEN-3694 + Pfizer Inc.s Talzenna (talazoparib).
  • The Phase 2b extension will enroll patients who have previously been treated with a TROP2 antibody drug conjugate for locally advanced or metastatic disease.
  • Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib), conducted in collaboration with Pfizer and Newsoara Biopharma.
  • Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab, conducted by the National Cancer Institute in collaboration with Zenith and BMS.

Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting

Retrieved on: 
Monday, April 11, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Treatment, Private Securities Litigation Reform Act, Therapy, Clonal hematopoiesis, Research, Risk, SEC, Head, Progression-free survival, Medical director, MBBS, Neoplasm, Ataxia–telangiectasia, MD, SETD2, Data, AMF, ATM, CPSA, CRISPR, Security (finance), ORR, BRCA2, Anemia, CHIP, Institute, U.S. Securities and Exchange Commission, Department, MD Anderson Cancer Center, PKMYT1, PARP, Talazoparib, DNA, Forward-looking statement, LOF, Clinical trial, Pharmacokinetics, RECIST, FRCP, Doctor of Philosophy, ATR, Ovarian cancer, STEP2, Associate professor, Melanoma, Patient, Company, BRCA1, Genome, Parpi, RAD51C, Platinum, PFS, CA125, Safety, CBR, COVID-19, Breast cancer, Division, Pharmaceutical industry, Medical imaging, Reparenting

Our comprehensive new dataset shows ATM loss of function as a compelling opportunity to offer durable clinical benefit to patients with genetically defined tumors.

Key Points: 
  • Our comprehensive new dataset shows ATM loss of function as a compelling opportunity to offer durable clinical benefit to patients with genetically defined tumors.
  • The Company will subsequently host a conference call today, April 11th at 6:30 p.m. Eastern Time to discuss the latest results from the TRESR trial.
  • Key highlights from the data presented at the 2022 AACR Annual Meeting include:
    RP-3500 monotherapy continues to appear safe and well tolerated.
  • Clinical benefit was also observed in patients with tumors harboring BRCA1 and BRCA2 genomic alterations, as predicted by SNIPRx.

Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress

Retrieved on: 
Monday, March 7, 2022
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Risk, Private Securities Litigation Reform Act, Patient, Pharmacokinetics, Research, AMF, Treatment, Forward-looking statement, Toxicity, Security (finance), Doctor of Philosophy, Safety, DNA, U.S. Securities and Exchange Commission, Anemia, Genome, Therapy, Congress, High, CRISPR, SEC, Company, COVID-19, Talazoparib, ESMO, Key finding attacks, TAT, ATR, Neoplasm, Clinical trial, MD, ATM, Pharmaceutical industry, Medical imaging, Reparenting, Repare Therapeutics’ SNIPRx® Platform, Repare Therapeutics, Inc., Repare Therapeutics’ SNIPRx® Platform, Repare Therapeutics, Inc., REPARE THERAPEUTICS’ SNIPRX® PLATFORM, REPARE THERAPEUTICS, INC.

The data featured today at ESMO TAT continues to show that RP-3500 is well tolerated.

Key Points: 
  • The data featured today at ESMO TAT continues to show that RP-3500 is well tolerated.
  • The dose optimization approach used in the trial provides robust evidence to support the recommended phase two dose and schedule in our ongoing trials.
  • We believe these data confirm a well differentiated and likely best in class profile of RP-3500, said Maria Koehler, MD, PhD, Chief Medical Officer of Repare.
  • We look forward to presenting updated clinical data from 120 patients enrolled in the Phase 1/2 TRESR trial in the first half of this year.

CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

Retrieved on: 
Monday, February 7, 2022
GLOBE, CD71, Head, Hematology, Medicine, Internal medicine, Chicago (franchise), Northwestern Memorial Hospital, Thomas Jefferson University, Twitter, Cancer, ADC, Therapy, CD166, Amgen, Technology, University, Talazoparib, AbbVie, CD3, Breast cancer, Bi-specific T-cell engager, BeiGene, Conquer, Genentech, Nasdaq, Bristol Myers Squibb, LinkedIn, Â, Medivation, SAN, Management, Oncology

Dr. Peterson has served as the companys executive vice president and chief development officer since October 2019 and will continue to report to Sean McCarthy, D.

Key Points: 
  • Dr. Peterson has served as the companys executive vice president and chief development officer since October 2019 and will continue to report to Sean McCarthy, D.
  • I am delighted to announce Amys advancement to president and chief operating officer.
  • Over the past two years, as our chief development officer, Amy has applied her exceptional combination of clinical development, operating and strategic experience to advance and broaden the CytomX Probody Therapeutic pipeline, said Sean McCarthy, D.Phil., chief executive officer and chairman.
  • In her newly expanded role, Amy will continue to leverage her strong leadership skills and her results-oriented approach to position CytomX for future success.

Triple-Negative Breast Cancer Disease Market Analysis Report 2021-2027 - Keytruda will Overtake Tecentriq in the TNBC Market - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Growth, Patient, Triple-negative breast cancer, Breast cancer, PTEN, HER2, Roche, Probability, PARP, Oncology Drug Advisory Committee, Immunotherapy, CXCR4, Patent, Pembrolizumab, Talazoparib, Cancer Drugs Fund, TNBC, Biomarker, Hypersensitivity, Chugai Pharmaceutical Co., PIK3CA, Fast Track, Paclitaxel, Phase, Protein kinase B, FDA, Bevacizumab, Pharmaceutical industry, Atezolizumab, Sacituzumab govitecan, EU

The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide.

Key Points: 
  • The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide.
  • By 2027, incident and five-year prevalent cases of breast cancer are expected to increase to 2.3 million and 9.3 million cases, respectively.
  • The market for TNBC is also becoming increasingly segmented by biomarker status, creating fierce competition among both approved and pipeline therapies for small patient populations.
  • Breast cancer drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.